title: Do patients with acute myocardial infarction benefit from treatment with clopidogrel?
abstract: Clopidogrel (Plavix), a platelet aggregation inhibitor, has been shown to be effective in certain patients undergoing percutaneous coronary interventions, but its use in patients with acute myocardial infarction who receive a fibrinolytic strategy instead has been controversial. The aim of the Evidence-Based Medicine (EBM) Section is to bring the readership clinically relevant and practical evidence-based medicine principles and topic reviews. This EBM - Therapy review focuses on a relatively new therapy option for Emergency Department patients with acute myocardial infarction.
authors.affiliation: Division of Emergency Medicine, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Andrew
authors.initials: A
authors.lastname: Worster
authors.forename: Samuel M
authors.initials: SM
authors.lastname: Keim
authors.forename: Rajiv
authors.initials: R
authors.lastname: Vadera
authors.forename: Peter
authors.initials: P
authors.lastname: Rosen
mesh_terms: D000328:Adult; D000077144:Clopidogrel; D004632:Emergency Medical Services; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine